$prqr And this is what I saw in a number of $lly job postings over the last few months: RNA, neurodegenerative, chronic pain.

Developers of fully synthetic human relaxin­2 bashing $lly and all others such as $azn and $TECX in this field for "meticulous up­engineering of half­life" achieved "at cost of essential signalling pathways" researchgate.net/publication/38…

$cdxs Enzymatic siRNA manufacturing reaches its next important milestone. Very nicely aligned with expansion of siRNA into new large indications that we're experiencing now. Best team both business and science wise codexis.com/investors/news…

$wve WVE-003 and WVE-006 somehow were completely ignored by this poster. As always - listen to everyone, trust no one, do your own DD

Honestly, guys - anyone who is selling biotech shares at this price should never have bought them… Yes, there’s turmoil - but nothing that changes the long-term value proposition $XBI

House is an honest and hard working dude. This is not your typical twitter spam thing.

$sgmt from Ascletis annual report (posted around March 26) ASC-40 is Denifanstat

$sgmt FASN Inhibitors in cancer treatments - podcast jumpshare.com/s/V4UbyUcycVLe…

Also fiercebiotech.com/biotech/alis-o… $xbi It's time to return cash to shareholders. Biotech Hangout fyi

$XBI We need an ETF traded under $SHIT ticker. Investment strategy - clinical and preclinical public bios traded at below 50% of cash on hand

$sgmt Denifanstat (ASC40) phase 3 acne Chinese trial results will be presented on June 20 in Rome. Looks like NOT a late breaker session, so we're waiting for Ascletis Pharma to PR phase 3 results before mid June.

This is the greatest social experiment ever conducted: He created a fake restaurant on TripAdvisor. No food. No staff. No venue. Yet it became the #1 ranked restaurant in London... Here's how he pulled it off:

$xbi Also expect that 30-80% of water will be turned into wine, and 30-80% Lazarus that were dead for less than four days will be raised from the dead.

This nation needs PBM reform to cut drugs prices. THEY are the real cause of high drugs prices in the US. Our scientists are the best in the world. Our health insurance companies are siphoning off profits making our drugs expensive.

$sgmt Denifanstat phase 3 monotherapy is withdrawn with "business decision" as a justification. Sagimet Biosciences I get this, securing $200M+ to run phase 3 alone for a $100M company is not possible in this market. Sell Deni now. $mdgl needs a pipeline, you need money to fund acne.

$pfe We don't always go to China for new molecules, but when we do we pay outrageously high upfront fees to look that we licensed something really good